Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announces that its clinical trial application of independently developed 9MW3811 injection for advanced malignancies and idiopathic pulmonary fibrosis has been approved by National Medical Products Administration (NMPA).

9MW3811 is a humanized monoclonal antibody against human interleukin-11 (IL-11) independently developed by Mabwell, belonging to Category 1 Therapeutic Biological Products. 9MW3811 can effectively block the activation of the downstream signaling pathway of IL-11 and inhibit the pathophysiological functions induced by IL-11, thereby achieving the therapeutic effect on fibrosis and tumor. 

Preclinical study showed that 9MW3811 bound to IL-11 with high affinity, effectively blocked the activation of IL-11 signaling pathway, specifically regulated the interaction of tumor cells with T cells, macrophages, and tumor-associated fibroblasts, and thus enhanced the release of inflammatory cytokines in the tumor microenvironment, and increased the infiltration of T cells. Combination anti-tumor efficacy with anti-PD1 antibodies has been observed in a variety of solid tumor models. In preclinical studies of fibrotic diseases, 9MW3811 significantly reduced the area of pulmonary fibrosis, reduced the content of lung collagen and improved lung function in mice with fibrosis, making it a promising therapeutic agent for specific pulmonary fibrosis and other diseases.

9MW3811 was approved by the Australian Therapeutic Goods Administration (TGA) for clinical trials in February 2023. It is in dose escalation study and expected to have good safety profile according to existing data.